24 October 2012 -- The BIA has welcomed government proposals released today to make the UK a more favourable location for innovative biopharmaceutical research and development through its consultation on the Research and Bolar Exceptions.
The proposals seek to add clarity to the UK's position on the types of research and clinical trials that can be carried out in the UK without giving rise to a risk of patent infringement. In a submission to the government on a previous informal consultation in July 2011, the BIA called for a level playing field so that developers of innovative products were afforded the same level of protection and certainty as others.
Steve Bates, Chief Executive of the BIA, said:
"We welcome the government's commitment to reviewing this issue and ensuring everything is done to make the UK an attractive location to conduct research and clinical trials."
"Biopharmaceutical companies invest more in R&D in the UK than any other sector and we have all the tools to continue to develop new medicines for patients. We look forward to engaging with government on this issue to ensure any barriers to continued such investment is removed."
John Murphy, Chair of the BIA's Intellectual Property Advisory Committee, said:
"Companies need to have confidence and certainty in the legal framework within which they operate particularly where intellectual property is concerned."
"It is important to provide clarity regarding the UK's interpretation of the Research and Bolar Exceptions so that innovative drug developers operate on a level playing field and we hope this consultation will provide the opportunity to address these issues."
For further information, please contact Antonis Papasolomontos, Head of Public Affairs and Policy, on 020 7630 2188.
Founded over 20 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org
'The Research and Bolar Exceptions' consultation document can be found on the website of the Intellectual Property Office on the following link: http://www.ipo.gov.uk/pro-policy/consult/consult-live/consult-2012-bolar.htm The government first announced its intention to examine the issue as part of its Plan for Growth in March in March 2011.
Copies of the BIA's response to the Intellectual Property office's informal consultation on the Research and Bolar Exceptions in July 2011 can be found on the following link: https://www.bioindustry.org/document-library/the-research-and-bolar-exceptions-consultation-bia-response/